JRA or Juvenile rheumatoid arthritis is not just a single illness. It is, in fact, a group of illnesses of unidentified etiology. The manifestation is a chronic inflammation of the joint. Treatment advances in the last thirty years have altered the prognosis for the more acute types of this disease. The first treatment is limited with only the use of salicylates and other non-steroidal anti-inflammatory drugs or NSAIDs. The initial treatment resulted into numerous patients being bound to their wheelchairs. Some patients tried synovectomies to get rid of tissue excesses which result from uncontrolled arthritis. The second-line medicines that were added have improved the prognosis for those who suffered from JRA. It started with gold salt injection and gradually replaced by MTX or methotrexate which is a more effective solution. These drugs are administered with team approach background in centers of pediatric rheumatology. In there, occupational and physical therapies have allowed much improved physical functions. The introduction of etanercept (which is a biologic enemy of tumor necrosis factor or TNF) has introduced a new era in treatments. A few more biologic agents such as the anakinra (which is an IL-1 or interleukin-1 receptor opponent) could be used in some patients who are not responsive to second-line medication. The future holds an inhibition of IL-6 which could be effective in systemic sufferers with JRA with high levels.

The US records the prevalence of JRA at 10-20 cases in every 100,000 children. The prevalence data change (11 to 83 cases in every 100,000) and they depend upon the study location. Polyarticular and pauciarticular diseases are more frequent among girls while both males and females are affected with systemic-onset illness. JRA seems to occur more often in some populations such as the Native Americans, and also among the people of Norway and British Columbia. A study made in Sweden have recorded prevalence that is similar in Minnesota which is estimated at 85 cases in every 100,000 individuals.

There have been no quantified mortalities in JRA but the mortality rate is at less than 1%. This is usually linked with the evolution of illness to features of other rheumatic disorders (examples are SLE or systemic lupus erythmatosus or scleroderma. JRA patients could have some complications that are specific to their illness subsets. The most ordinary form of morbidity among patients relates to undesirable medical effects (especially with NSAIDs). Significant psychological morbidity (such as anxiety, depression, and the inability to focus in school) could occur in all sub-types.

juvenilerheumatoidarthritis